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One major obstacle in the clinical application of TRAIL as a cancer therapeutic agent is the acquisi-
tion of TRAIL resistance. We found that deﬁciency of TRADD sensitizes cells to TRAIL-induced apop-
tosis. Enhanced cell death in TRADD/ MEFs is associated with defective NF-jB activation,
indicating that the pro-survival function of TRADD in TRAIL signaling is mediated at least in part
via NF-jB activation. Moreover, siRNA knock-down of TRADD in cancer cells sensitizes them to
TRAIL-induced apoptosis. Thus, TRADD has a survival role in TRAIL signaling and may be one poten-
tial target for overcoming TRAIL resistance in cancer therapy.
Structured summary of protein interactions:
TRAIL physically interacts with FADD and RIP1 by pull down (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the pro-survival NF-jB activation since TRAIL does not induce NF-TNF Receptor-Associated Death Domain (TRADD) is an essential
mediator of TNF receptor-1 (TNFR1)-mediated TNF signaling and
is responsible for recruitment of other effector proteins, such as
RIP1 (Receptor Interacting Protein 1) and TRAF2 (TNF Receptor-
Associated Factor 2) to the TNFR1 signaling complex [1–4], and
FADD (Fas-Associated protein with Death Domain) to TNFR1-
induced secondary complexes [5]. Recruitment of these adaptor
proteins leads to the activation of MAP kinases and NF-jB, as well
as other signaling pathways, including cell death [2,6]. Like TNFR1,
TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2
contain a cytoplasmic death domain (DD) that associates with DD-
containing adaptor proteins such as FADD, TRADD, or RIP1 to trigger
cell signaling [7], although FADDmaybe involved in the recruitment
of secondary adaptors. TRAIL can activate the NF-jB and MAPK
signaling pathways [7,8], and NF-jB-mediated induction of anti-
apoptotic genes, such as inhibitors of apoptosis (IAPs) and Bcl-2
homologuesmaydetermine cellular susceptibility towardapoptosis
induction [9,10].
Here we show that TRADD deﬁciency renders cells more suscep-
tible to TRAIL-induced cell death. This is likely due to impairment ofchemical Societies. Published by E
ical Sciences, Ajou University
gu, Suwon 443-749, Republic
.jB activation in TRADD/ MEFs, while ectopic expression of p65
or IKKb prevents TRAIL-induced cell death in these cells. Despite
the fact that TRADD/ MEFs lack TRAIL-induced ERK and JNK
activation, the loss of these pathways does not contribute to
TRAIL-induced cell death in the knockout MEFs. Depletion of
TRADD in cancer cells potentiates TRAIL-induced cell death,
suggesting that TRADD is a potential target for sensitization to
TRAIL-mediated cancer chemotherapy.
2. Materials and methods
2.1. Reagents
Anti-phospho-ERK, anti-phospho-p38, anti-phospho-IjBa, anti-
ERK, anti-p38, anti-caspase 3, anti-caspase 8, and anti-PARP1 anti-
bodies were from Cell-Signaling. Anti-phospho-JNK antibody was
purchased from Biosource. Anti-TRADD, anti-FADD, and anti-IjBa
antibodies were from Santa Cruz. Anti-TRAIL-R and RIP1 antibodies
were fromBD. Cycloheximide, SP 600125, PD 98059, SB 202190, and
IKK-2 inhibitor V were from Calbiochem. Glutathione S-transferase
(GST)-TRAIL was described previously [11]. Recombinant murine
TRAIL and recombinant murine TNFawere from R&D.
2.2. Cell culture and treatment
Wild type and TRADD/MEFs [1–4] and HepG2 cells were cul-
tured in DMEMwith 10% FBS, 2 mM glutamine, 100 U/ml penicillin,lsevier B.V. All rights reserved.
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lines were selected in media containing 2 lg/ml puromycin.
2.3. Western blot analysis
Upon treatment, cells were lysed in M2 buffer (20 mM Tris at
pH 7, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM
DTT, 0.5 mM PMSF, 20 mM b-glycerol phosphate, 1 mM sodium
vanadate, 1 lg/ml leupeptin). Equal amounts of protein from each
cell lysates were resolved by 12% SDS–PAGE and visualized by en-
hanced chemiluminescence following the manufacturer’s instruc-
tion (ECL, Amersham).
2.4. Detection of cell cytotoxicity
Cell death was determined using tetrazolium dye colorimetric
tests (MTT), and alsomeasured by using a FITC-Annexin VApoptosisWT KOA
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Fig. 1. Deletion of TRADD sensitizes cells to TRAIL-induced cell death. (A, B) Phase contras
TRADD/MEFs treated with mouse recombinant TRAIL (40 ng/ml, 16 h). In panel B, cells
were similarly treated and apoptotic cell death was measured using PI/Annexin V.Detection kit (BD Phamingen) according to the manufacturer’s
protocol.
2.5. Transfection
Cells were transfected with HA-IjBa super suppression plas-
mid, HA-IKKb, and GFP-p65 or Mock vector with Lipofectamine
PLUS reagent according to manufacturer’s protocol (Invitrogen,
Inc.).
2.6. Small interfering RNA knockdown
HepG2 cells plated in 12-well plates were transfected with
50 pmol of TRADD or non-targeting control (NC) RNAi oligo
(Dharmacon) using Lipofectamine 2000 reagent (Invitrogen, Inc.).
After 48 h, cells were treatedwith GST-TRAIL for 12 h and LDH leak-
agewas quantiﬁed using a cytotoxicity detection kit (Promega). Cell120
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Detection kit (BD Phamingen).
2.7. GST-pull down assay
Wild type and TRADD/MEFs (1  108) cells were treated with
10 lg/ml GST-TRAIL for 15 min or left untreated. Cells were then
washed with PBS and lysed with M2 buffer. The soluble fraction
was incubated with 30 ll of 50% glutathione-Sepharose beads (GE
healthcare) for 3 h on a rotator at 4 C. Bound proteins were eluted,
resolved in 12% SDS–PAGE, and analyzed by immunoblotting.
3. Results
3.1. Deﬁciency of TRADD sensitizes cells to TRAIL-induced cell death in
MEFs
Treatment of TRADD/ MEFs with recombinant murine TRAIL
showed the TRADD/ MEFs were sensitive to TRAIL-induced cell
death, whilewild type (WT)MEFswere resistant, suggesting TRADDBA 120
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Fig. 2. TRADD deﬁciency sensitizes cells to apoptosis induced by TRAIL but not TNFa. (A
(40 ng/ml) or CHX (10 lg/ml) and TNFa (30 ng/ml) for 24 h (Error bars: +/ S.E.M.). In pa
TRAIL-treated wild type and TRADD/ MEFs.prevented TRAIL-mediated cell death under normal circumstances
(Fig. 1A). Cycloheximide sensitized WT MEFs to TRAIL, however,
TRADD/ MEFs continued to be more sensitive than the WT MEFs
to TRAIL as shown by contrast microscopy or MTT assay (Fig. 1B)
or by PI/Annexin V staining (Fig. 1C). Though TRADD/MEFs were
more sensitive to CHX plus TRAIL than WT cells, they were com-
pletely refractory to CHX plus TNFa (Fig. 2A), consistent with the
previous reports [1]. This suggests that TRADD/MEFs are notmore
generally susceptible to cell death, and that TRAIL-induced sensitiv-
ity is stimulus speciﬁc. Cell death induced by TRAIL was completely
blocked by zVAD, indicating that only apoptotic cell death was
occurring in the TRADD/MEFs (Fig. 2B). Consistent with this, we
detected fully processed caspase 8, caspase 3, and PARP-1 cleavage
in the TRAIL-treated TRADD/MEFs, but not in WT MEFs (Fig. 2C),
and zVAD efﬁciently blocked these events (Fig. 2D).
3.2. TRADD reconstitution suppressed TRAIL-induced apoptosis
We veriﬁed the involvement of TRADD in these events via stable
TRADD reconstitution in TRADD/MEFs (Fig. 3A). Reconstitution of120
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, B) MTT assays of WT and TRADD/MEFs treated with CHX (1 lg/ml) and mTRAIL
nel B, some cells were pretreated with zVAD (20 nM). (C, D) Immunoblot analysis in
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MEFs (Fig. 3B), but substantially blocked TRAIL-induced cell death
(Fig. 3C), conﬁrming that increased sensitivity of TRADD/ MEFs
to TRAIL was due to loss of TRADD.
3.3. TRAIL-induced NF-jB activation has pro-survival function in MEF
cells
TRAIL can activate the transcription factor NF-jB,which can pro-
tect from TRAIL-induced apoptosis [12–14]. To investigate whether
TRAIL-induced NF-jB activation requires TRADD, we treated WT
and TRADD/ MEFs with GST-TRAIL because we were able to in-
crease the activity inMEFs compared to rmTRAIL (see Fig. 4A for cell
death activity [11]). While GST-TRAIL activated IjBa phosphoryla-
tion anddegradation inWTMEFs, GST-TRAIL-inducedNF-jB activa-
tionwas non-existent in TRADD/MEFs (Fig. 4B). Reconstitution of
TRADDexpression restoredNF-jB activation in response to TRAIL as
well as to TNFa in TRADD/MEFs (Fig. 4C). These results strongly
suggest that TRADD is crucial for TRAIL-induced NF-jB activation
and impairedNF-jBactivation could explain theobserved sensitiza-
tion to TRAIL-induced apoptosis in TRADD-deﬁcient cells. Inhibition
of NF-jB activation by IjBa super suppressor inWTMEFs bestowed
sensitivity to TRAIL (Fig. 4D),while ectopic expression of IKKb or p65
rescued TRADD/MEFs (Fig. 4E) orHepG2 cells (Fig. 4F) in response
to TRAIL. Taken together, our data suggest that TRADD protects cells
from TRAIL-induced cell death through NF-jB activation.
3.4. Impaired JNK and ERK activation by TRAIL in TRADD/ MEFs
MAPKs are readily activated in response to various stresses, and
play key roles in deciding cell fate [15,16]. TRADD/ MEFs lacked
TRAIL-induced activation of ERK and JNK, while the activation ofA
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Fig. 3. Reconstitution of TRADD in TRADD/ MEFs blocks TRAIL-induced cell death. (A
mTRADD) MEFs. (B, C) MTT assays of cells from A treated with CHX (10 lg/ml) and TNFa
S.E.M.).p38 was not affected (Fig. 5A). However, the MAPK inhibitors, SP
600125 for JNK, PD 98059 for ERK, and SB 202190 for p38, respec-
tively, did not inﬂuence TRAIL-induced cell death in either WT and
TRADD/ MEFs (Fig. 5B), indicating that TRAIL-induced cell death
in MEFs is independent of MAPK activity. In contrast, when NF-jB
activation was blocked in WT MEFs or HepG2 cells through IKK
inhibition, TRAIL-induced cell death was dramatically increased
(Fig. 5C and 5D) suggesting the NF-jB defect is responsible for
the their susceptibility to TRAIL-induced cell death.
3.5. Knockdown of TRADD sensitizes cancer cells to TRAIL-induced cell
death
TRAIL a highly promising cancer therapeutic agent, however,
cancer cells can acquire resistance to TRAIL-induced cytotoxicity.
We sought to determine whether TRADD knockdown can also sen-
sitize cancer cells to TRAIL. Knockdown of TRADD expression in
HepG2 cells (Fig. 6A) led to an increased sensitivity of HepG2 cells
to TRAIL (Fig. 6B and 6C), suggesting that targeting TRADD is able
to sensitize human cancer cells to TRAIL-induced cytotoxicity.
3.6. TRAIL-induced DISC complex formation
Finally, we investigated recruitment of signaling adaptors to the
TRAIL receptor. We were able to detect RIP1 in the complex in both
MEF cell types (Fig. 7), though RIP1 recruitment to the receptor
complex lasted longer in TRADD/ MEFs. Although less clear,
FADD recruitment to the DISC also appeared to slightly increase
in TRADD/ MEFs, (Fig. 7). We therefore hypothesize that TRADD
may compete with FADD and/or RIP1 for DISC recruitment and the
additional FADD recruitment in TRADD/MEFs may contribute to
enhanced sensitivity to TRAIL-induced cell death.ADD
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Fig. 4. TRAIL-induced NF-jB activation is impaired in TRADD/ MEFs. (A) Wild type and TRADD/MEFs were treated with CHX (0.1 lg/ml) or CHX /GST-TRAIL (10 lg/ml)
for 16 h and viability was analyzed by MTT assay. (B, C) Immunoblots from cell lysates of wild type, TRADD/ (B) or stably transfected TRADD/ (Flag-mTRADD) MEFs (C)
treated with GST-TRAIL (10 lg/ml) or TNFa (30 ng/ml) for indicated timepoints. (D–F) MTT assay of cells transfected with IjBa super suppressor, IKKb, p65 (RelA), or empty
vector, then treated with GST-TRAIL (D, E: 10 lg/ml for WT and TRADD/ MEFs and F: 50 ng/ml for HepG2 cells) for 24 h (A, D, E, F Error bars: +/ S.E.M.).
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TRAIL is selective cytotoxic in cancer cells and therefore a prom-
ising anti-cancer therapeutic agent. However, cancer cells often ac-
quire TRAIL resistance and underlying molecular mechanisms are
still elusive. To gain better understanding of TRAIL-induced signal-
ing, we investigated that function of TRADD in this pathway. Deﬁ-
ciency of TRADD sensitizes cells to TRAIL’s cytotoxicity, and
cytotoxicity is blocked when TRADD expression is reconstituted.
Thus, TRADD plays a protective role against TRAIL-induced cell
death.
Our data indicate that TRAIL-induced NF-jB activation has pro-
survival role in MEFs and TRADD is required for activation of this
signaling pathway. This is consistent with several earlier reports
showing the anti-apoptotic function of NF-jB in TRAIL-induced cell
death [11]. For instance, Lluis et al. showed that NF-jB negatively
regulated TRAIL induced cell death in TAK1 knockout MEFs byincreasing c-FLIPL levels [17] and a speciﬁc IKK inhibitor BMS-
345541 or expression of IjBaM,which inhibits constitutively active
NF-jB, confers sensitivity to TRAIL-induced cell death [18]. In addi-
tion, IKKc/MEFs are sensitive to TRAIL-induced cytotoxicity [17].
Although our data suggest that lack of NF-jB activation is the
primary reason for TRAIL-induced death of TRADD/ cells, we do
not exclude the possibility that TRADD also limits FADD recruit-
ment to the DISC and that TRADD depletion results in greater FADD
recruitment, as has been recently suggested [19]. We saw some
evidence that this could be the case. Most likely both mechanisms
play a role in the sensitivity of TRADD/ cells to TRAIL. In contrast
to this previous study [19], we observed that RIP1 was recruited to
the TRAIL receptor complex in the absence of TRADD, and addi-
tional RIP1 recruited, suggesting that NF-jB deﬁciency occurs from
loss of another TRADD-recruited component, such as cIAPs, that
are necessary for NF-jB activation, and not from loss of RIP1
recruitment. Additional RIP1 recruitment in the absence of NF-jB
A WT                         KO
GST-TRAIL  0  15  30 60 120 240 0   15  30 60 120 240 (min)
p-ERK
ERK
p-JNK
JNK
p-p38
p38
B
120
140
WT KO
100
80
60
40
20
w/o w/o SP PD SB
0
CHX+GST-TRAIL
C DWT MEF
120
HepG2
120 
100al 100 va
l
80
ur
vi
va
80 
ur
vi
v
60
el
l s
u
60 el
l s
u
40
%
 C
e
40 %
 C
20
%
20 
0
IKK inhibitor - - + + IKK inhibitor    - - +       +            
0 
GST-TRAIL    - +      - + GST-TRAIL    - +      - +
Fig. 5. TRAIL-induced JNK and ERK activation are impaired in TRADD/ MEFs, but do not contribute to cell death sensitivity. (A) Immunoblot analysis of wild type and
TRADD/MEFs treated with GST-TRAIL (10 lg/ml) for indicated timepoints. (B) MTT assay of wild type and TRADD/MEFs pretreated with MAPK inhibitors, SP, PD, and SB
for 30 min before CHX and GST-TRAIL (10 lg/ml) treatment for overnight. (C and D) MTT assay of wild type MEFs (C) and HepG2 cells (D) pretreated with IKK-2 inhibitor V for
30 min before GST-TRAIL treatment (24 h). (B–D Error bars: +/ S.E.M.).
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TRAIL as has been suggested for Fas [20].There is mounting evidence that inhibition of NF-jB signaling
leads to TRAIL-resistance by upregulating anti-apoptotic genes in
GST pull down Input-
WT               KO               WT             KO   
RIP1
TRAIL    0   15   30    0   15   30      0   15  30   0   15   30  (min)
FADD
TRAIL-R
Fig. 7. GST-pull down assay. DISC formation was detected by GST-pull down assay.
WT and TRADD/ MEFs were treated with GST-TRAIL (10 lg/ml) for indicated
timepoints and GST-TRAIL-bound protein complexes were pulled down by gluta-
thione-agarose beads and analyzed for presence of RIP1 and FADD by western blot.
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cer cells increases TRAIL-induced cell death, TRADD could therefore
serve as a target for sensitizing cancer cells to TRAIL cytotoxicity.Acknowledgements
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